US20120028945A1 - 5-Beta, 14-Beta-Androstane Derivatives Useful For The Treatment Of Proteinuria, Glomerulosclerosis And Renal Failure - Google Patents

5-Beta, 14-Beta-Androstane Derivatives Useful For The Treatment Of Proteinuria, Glomerulosclerosis And Renal Failure Download PDF

Info

Publication number
US20120028945A1
US20120028945A1 US13/258,728 US201013258728A US2012028945A1 US 20120028945 A1 US20120028945 A1 US 20120028945A1 US 201013258728 A US201013258728 A US 201013258728A US 2012028945 A1 US2012028945 A1 US 2012028945A1
Authority
US
United States
Prior art keywords
furyl
androstane
diol
ethoxy
pyrrolidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/258,728
Other languages
English (en)
Inventor
Patrizia Ferrari
Giuseppe Bianchi
Mara Ferrandi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Assigned to SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. reassignment SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FERRANDI, MARA, BIANCHI, GIUSEPPE, FERRARI, PATRIZIA
Publication of US20120028945A1 publication Critical patent/US20120028945A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Definitions

  • the present invention relates to 17- ⁇ -(3-furyl) and (4-pyridazinyl)-5- ⁇ , 14- ⁇ -androstane derivatives, as useful agents for preparing a medicament for the prevention and treatment of proteinuria, glomerulosclerosis and renal failure.
  • proteinuria derives from protein and urine and means the presence of an excess of serum proteins in the urine. Proteinuria may be a sign of renal (kidney) damage, since serum proteins are readily reabsorbed from urine, the presence of excess protein indicates either an insufficiency of absorption or impaired filtration.
  • Proteinuria may be a feature of the following conditions: Nephrotic syndromes (i.e. intrinsic renal failure); toxic lesions of kidneys; Collagen vascular diseases (e.g., systemic lupus erythematosus); Glomerular diseases, such as membranous glomerulonephritis, focal segmental glomerulonephritis; Strenuous exercise; Stress; Diabetes mellitus; Drugs (e.g., NSAIDs, nicotine, penicillamine, gold and other heavy metals, ACE inhibitors, antibiotics, opiates especially heroin); Infections (e.g., HIV, syphilis, hepatitis, post-streptococcal infection); Aminoaciduria; Hypertensive nephrosclerosis; Interstitial nephritis and Glomerulosclerosis.
  • Nephrotic syndromes i.e. intrinsic renal failure
  • Collagen vascular diseases e.g., systemic lupus erythemat
  • Glomerulosclerosis is a general term to describe scarring of the kidneys' tiny blood vessels, the glomeruli, the functional units in the kidney that filter urine from the blood. Many patients with glomerulosclerosis gradually get worse until their kidneys fail completely. This condition is called end-stage renal disease or ESRD. Patients with ESRD must go on dialysis (hemodialysis or peritoneal dialysis) to clean their blood or get a new kidney through transplantation.
  • dialysis hemodialysis or peritoneal dialysis
  • the kidney glomerulus is a highly specialized structure that controls the plasma ultrafiltration of proteins.
  • the specific cellular unit that ensures this control is the podocyte whose dysfunction is involved in a massive loss of proteins in the urine (proteinuria). It is well known that podocyte function is strictly under the control of specific proteins modulating the actin cytoskeleton. Mutations into the genes coding for such podocyte proteins are known to be associated with alterations of the glomerular membrane barrier and consequently with massive proteinuria and renal damage.
  • nephrin is a fundamental constituent of the slit pore membrane and modulates the cytoskeleton dynamics through the activation of a signal transduction pathway mediated by the tyrosin kinase Fyn which belongs to the Src family kinases (Trends Mol. Med. 2007; 13: 396-403).
  • Adducin is a cytoskeletal protein involved in the regulation of the actin-spectrin dynamics in all the cells. Polymorphisms of the adducin genes have been demonstrated to be associated with hypertension and progression of the renal failure.
  • the knockout mice for mutant ⁇ adducin which are normotensive, show an increased expression of podocyte proteins, such as nephrin, synaptopodin, ⁇ -actinin, Fyn and ZO-1 and a reduction of urinary protein ( FIG. 1 ), as compared with control mice, indicating a possible role of ⁇ adducin in the modulation of glomerular permeability independent from the blood pressure control.
  • podocyte proteins such as nephrin, synaptopodin, ⁇ -actinin, Fyn and ZO-1
  • a reduction of urinary protein FIG. 1
  • Endogenous Ouabain has been widely recognized as a new hormone able to control blood pressure through different mechanisms and mainly through the modulation of the renal Na handling. High circulating levels of EO have been found associated with high blood pressure.
  • EP0583578B1 describes the beta-androstane derivatives claimed in the present application, a process for their preparation and their use for the treatment of cardiovascular disorders such as heart failure and hypertension.
  • EP0590271B1 describes 17-aryl and 17-heterocyclyl-5-alpha, 14- ⁇ -androstane, androstene and androstadiene derivatives, a process for their preparation and their use for the treatment of cardiovascular disorders such as heart failure and hypertension.
  • EP0590272B1 describes 17-aryl and 17-heterocyclyl-5- ⁇ , 14- ⁇ -androstane derivatives and their use for the treatment of cardiovascular disorders such as heart failure and hypertension.
  • WO2008148812 describes 17- ⁇ -(3-furyl) and (4-pyridazinyl)-5-beta, 14-beta-androstane derivatives and their use for treatment of restenosis after angioplastic or endoartherectomy, and diseases due to organ fibrosis.
  • 17- ⁇ -(3-furyl) and (4-pyridazinyl)-5- ⁇ , 14- ⁇ -androstane derivatives according to the present invention are useful agents for the prevention and treatment of proteinuria, glomerosclerosys and renal failure.
  • Y is oxygen or guanidinoimino when in position 3 is a double bond
  • Y is hydroxy, OR 4 or SR 4 , when in position 3 is a single bond and can have an alpha or beta configuration;
  • R is an unsubstituted or substituted 3-furyl or 4-pyridazinyl group
  • R 1 is hydrogen; methyl; ethyl or n-propyl substituted by OH or NR 5 R 6 ;
  • R 2 is hydrogen or together to R 3 is a bond of an oxirane ring
  • R 3 is hydrogen or together to R 2 is a bond of an oxirane ring
  • R 4 is hydrogen; methyl; C2-C6 alkyl or C3-C6 alkenyl or C2-C6 acyl, these alkyl, alkenyl and acyl groups being unsubstituted or substituted by a quaternary ammonium group or one or more OR 7 , NR 8 R 9 , formyl, amidino, guanidinoimino or by NR 8 R 9 and hydroxy;
  • R 5 , R 6 are independently hydrogen; methyl; C2-C6 alkyl unsubstituted or substituted by one NR 10 R 11 , or NR 10 R 11 and hydroxy, or R 5 and R 6 taken together with the nitrogen atom form an unsubstituted or substituted saturated or unsaturated penta- or hexa-monoheterocyclic ring, optionally containing another heteroatom chosen from oxygen or sulfur or nitrogen;
  • R 7 is hydrogen, methyl or C2-C4 alkyl, this alkyl being unsubstituted or substituted by one or more NR 10 R 11 or by NR 10 R 11 and hydroxy;
  • R 8 , R 9 are independently hydrogen; methyl; C2-C6 alkyl or C3-C6 alkenyl, these alkyl and alkenyl groups being unsubstituted or substituted by one or more NR 10 R 11 , or NR 10 R 11 and hydroxy, or R 8 and R 9 taken together with the nitrogen atom form an unsubstituted or substituted saturated or unsaturated penta- or hexa-monoheterocyclic ring, optionally containing another heteroatom chosen from oxygen or sulfur or nitrogen, or R 8 is hydrogen and R 9 is amidino; or NR 8 R 9 represents propargylamino;
  • R 10 , R 11 are independently hydrogen, C1-C6 alkyl, or R 19 and R 11 , taken together with the nitrogen atom form a saturated or unsaturated penta- or hexa-monoheterocyclic ring;
  • compositions which retain the biological activity of the base and are derived from such known pharmaceutically acceptable acids such as hydrochloric, sulfuric, phosphoric, malic, tartaric, maleic, citric, methanesulfonic or benzoic acid;
  • the alkyl and alkenyl groups may be branched or straight chain groups
  • the C1-C6 alkyl group is preferably a C1-C4 alkyl group, e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl;
  • the C2-C6 alkyl group is preferably a C2-C4 alkyl group, e.g. ethyl, n-propyl, isopropyl, n-butyl, sec-butyl;
  • the C3-C6 alkenyl group is preferably a C3-C4 alkenyl group, e.g. 2-propenyl, 2-butenyl;
  • the C2-C6 acyl is preferably a C2-C4 acyl group, e.g. acetyl, propionyl, butyryl;
  • the quaternary ammonium group is preferably a trimethylammonium- or a N-methylpyrrolidinium- or a N-methylpiperidinium-group;
  • the OR 7 group is preferably hydroxy, 2-aminoethoxy, 3-aminopropoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 3-dimethylaminopropoxy, 3-amino-2-hydroxypropoxy, 2,3-diaminopropoxy, 2-(1-pyrrolidinyl)ethoxy, 3-(1-pyrrolidinyl)propoxy,
  • the NR 5 R 6 group is preferably amino, methylamino, ethylamino, n-propylamino, dimethylamino, diethylamino, pyrrolidinyl, morpholino, piperazinyl, 1-imidazolyl, 2-aminoethylamino, 3-aminopropylamino;
  • the NR 8 R 9 group is preferably amino, methylamino, ethylamino, n-propylamino, iso-propylamino, allylamino, propargylamino, dimethylamino, diethylamino, pyrrolidinyl, morpholino, piperazinyl, 1-imidazolyl, 1-guanidino, 2-aminoethylamino, 3-aminopropylamino, 2-(1-pyrrolidinyl)ethylamino, 3-(1-pyrrolidinyl)propylamino, 3-amino-2-hydroxypropylamino, 3-(1-pyrrolidinyl) 2-hydroxypropylamino, 2,3-diaminopropylamino , (2-(1-pyrrolidinyl)ethyl)methylamino;
  • Preferred examples of specific compounds according to the present invention are:
  • the most preferred example of specific compound according to the present invention is 17- ⁇ -(3-Furyl)-5- ⁇ -androstane-3- ⁇ , 14- ⁇ , 17- ⁇ -triol, in the following mentioned as “rostafuroxin” or “PST 2238”.
  • therapeutically effective amount refers to an amount of a therapeutic agent needed to treat, ameliorate a targeted disease or condition, or to exhibit a detectable therapeutic effect.
  • the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs.
  • the animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • an effective amount for a human subject will depend upon the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination (s), reaction sensitivities, and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, an effective dose per day will be from 0.05 mg to 20 mg, preferably 0.5 mg to 15 mg, most preferably 5 mg to 10 mg.
  • Dosage treatment may be a single dose schedule or a multiple dose schedule, according to the physician judgement.
  • compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones.
  • the medicament may also contain a pharmaceutically acceptable carrier, for administration of a therapeutic agent.
  • a pharmaceutically acceptable carrier for administration of a therapeutic agent.
  • Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity.
  • Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.
  • Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.
  • compositions of the invention can be administered directly to the subject.
  • the subjects to be treated can be animals; in particular, human subjects can be treated.
  • the medicament of this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, rectal means or locally on the diseased tissue after surgical operation.
  • the compound of the invention may also be applied (coated) on the stent even incorporated into a controlled-release matrix.
  • FIG. 1 represents the level of urinary protein excretion (mg/6 h) in mice carrying the knockout (KO) of the beta adducin as compared with the wild type (WT) controls.
  • Male mice were 11 month-olds and urinary protein excretion was measured on urine collected for 6 hours from each mouse housed in metabolic cage. Data are mean ⁇ sem of 15 WT and 19 KO mice.
  • Statistical analysis was carried out by t Student's test. The figure shows that the 6 hour-urinary protein excretion was significantly decreased (by 30%) in KO mice for beta adducin as compared to WT controls.
  • FIG. 2 represents the amount of podocyte proteins (nephrin, ⁇ -actinin, ZO-1, podocin, ⁇ -adducin and actin) expressed in cultured podocytes obtained from neonatal ( ⁇ 10-day-old) rats from the congenic NB and NA strains.
  • Podocyte proteins were quantified on podocyte extracts by Western blotting with appropriate antibodies (see the representative traces on the top of bars). Data are reported as mean ⁇ sem of several experiments ranging from 4 to 24 for each strain. Statistical analysis was carried out by t Student's test.
  • the figure shows that the amounts of Nephrin, ⁇ -Actinin, ZO-1, Podocin and ⁇ -Adducin are significantly reduced in podocytes from NB normotensive rats carrying the mutant ⁇ -adducin as compared to NA controls carrying the wild type variant, while the housekeeper protein actin is similar.
  • FIG. 3 represents the expression of some podocyte proteins (Nephrin, Synaptopodin, ⁇ -Actinin, ZO-1, Fyn and Vimentin) as detectable by immunofluorescence in renal glomeruli from NB normotensive rats carrying the mutant (3-adducin as compared to NA controls carrying the wild type variant.
  • the figure shows that the expression of these proteins is drastically reduced in NB as compared to NA rats, while Vimentin, a microfilament localized in the podocyte cell body, is normally expressed in the two strains.
  • FIG. 4 shows the progression of renal failure evaluated as the decay of glomerular filtration rate (GFR) over time (ml.min ⁇ 1 .year ⁇ 1 ) in patients affected by IgA nephropathy subdivided in 4 groups according to ⁇ -adducin (ADD1, Gly460Tyr) and ⁇ -adducin (ADD2, C399T) genotypes. The interaction between the two genes on the rate of decay was found significant.
  • GFR glomerular filtration rate
  • FIG. 5 represents the amount of podocyte proteins (nephrin, ZO-1, podocin, ⁇ -adducin, synaptopodin and actin) expressed in cultured podocytes obtained from neonatal ( ⁇ 10-day-old) rats from the congenic NB strain and incubated for 5 days with or without Rostafuroxin 10-9M.
  • Podocyte proteins were quantified on podocyte extracts by Western blotting with appropriate antibodies. Data are reported as mean ⁇ sem of several experiments. Statistical analysis was carried out by t Student's test. The figure shows that the amounts of Nephrin, ZO-1, Podocin, ⁇ -Adducin and Synaptopodin, but not Actin, are increased in podocytes cultured in the presence of 10 ⁇ 9 M Rostafuroxin.
  • FIG. 6 represents the systolic blood pressure (SBP), urinary protein excretion and amount of Nephrin from renal cortex of rats chronically infused with ouabain (OS) and treated with vehicle as compared either to control saline infused rats or OS rats orally treated for 8 weeks with Rostafuroxin 100 ⁇ g/kg/day. Data are reported as mean ⁇ sem of 8 rats for each group. Statistical analysis was carried out by t Student's test. The figure shows that Rostafuroxin significantly reduced SBP and urinary protein excretion while it increased Nephrin expression in OS rats, thus antagonizing the renal effects of ouabain.
  • SBP systolic blood pressure
  • OS ouabain
  • congenic NB rats carrying the beta adducin mutation (Tripodi G. et al. Effect of Add 1 gene transfer on blood pressure in reciprocal congenic strains of Milan rats. BBRC 2004; 324: 562-568) were used. Said NB rats are non-hypertensive rats and are available at Prassis Research Institute, Sigma-tau, Italy.
  • NB rats of 7 to 10 days of age were used for podocyte isolation and culture.
  • Podocyte proteins were quantified at the end of the 5 days of incubation by Western blotting. The quantification by Western blot was replicated two to three times for each podocyte marker.
  • the densitometric analysis was quantified as optical density, in arbitrary units.
  • Glomeruli were isolated from NB kidneys by sieving and further manually purification. Glomeruli were then seeded in culture flasks (Corning, Sigma-Aldrich, Milan, Italy), pre-coated with collagen type IV (Sigma-Aldrich) at 37° C. in 5% CO 2 atmosphere. On days 4 to 5, podocyte growth started and, by day 8, glomeruli were detached using trypsin-EDTA. Second passage podocytes, which resulted in >90% pure as judged by light microscopy inspection, were seeded on flasks and chamber slides. Podocyte protein quantification (10 ⁇ g protein/lane) was performed by Western blotting technique by using specific antibodies against nephrin, podocin, ZO-1, adducin, synaptopodin and actin.
  • the results obtained indicate that the compound of the invention is able to antagonize the podocyte protein loss induced by beta adducin mutation thus favouring the correct function of the glomerular filtration barrier and reducing proteinuria in a normotensive experimental model.
  • Systolic blood pressure (SBP) and heart rate (HR) were measured weekly in conscious rats by tail-cuff plethysmography (BP recorder, U. Basile, Italy).
  • Urinary parameters were measured in conscious OS and control rats at the 12 th week of treatment. Rats were housed in individual metabolic cages and acclimated for one day. 24-hours urines collection started at 9 a.m. During urine collection, rats had free access to water and food. After centrifugation (4500 rpm for 20 min; Varifuge 3.2 RS, Haereus Instruments, AHSI, Milan, Italy), rat urines were analyzed for the urinary volume (ml), quantified by weighing the urinary reservoir on a precision Mettler balance; urinary pH (pHM83, Radiometer, Copenhagen) and total urinary protein excretion (mg/24 h), measured with a standard total protein Kit (Sentinel Diagnostics, Milan, Italy).
  • renal cortical microsomes were prepared from each rat and nephrin, the key protein of the slit diaphragm membrane, was quantified by Western blotting.
  • Samples were separated by SDS-polyacrylamide gel electrophoresis, blotted and overnight incubated at 4° C. with specific primary antibodies (anti-nephrin from Santa Cruz; anti-actin from Sigma-Aldrich), followed by 1 h incubation with fluorescent secondary antibodies (Alexa Fluor), then analyzed and quantified by Odyssey Infrared Imaging detection system (LI-COR Biosciences). Nephrin quantification is expressed as optical density, arbitrary units.
  • the results obtained indicate that the compound of the invention is able to antagonize the pathological effects of ouabain on blood pressure, urinary protein excretion and glomerular protein loss thus lowering blood pressure, re-establishing the glomerular nephrin expression and reducing proteinuria.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US13/258,728 2009-03-23 2010-03-18 5-Beta, 14-Beta-Androstane Derivatives Useful For The Treatment Of Proteinuria, Glomerulosclerosis And Renal Failure Abandoned US20120028945A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09155834 2009-03-23
EP09155834.6 2009-03-23
PCT/EP2010/053571 WO2010108855A1 (en) 2009-03-23 2010-03-18 5-β, 14-β-ANDROSTANE DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEINURIA, GLOMERULOSCLEROSIS AND RENAL FAILURE

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/053571 A-371-Of-International WO2010108855A1 (en) 2009-03-23 2010-03-18 5-β, 14-β-ANDROSTANE DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEINURIA, GLOMERULOSCLEROSIS AND RENAL FAILURE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/931,083 Continuation US9868757B2 (en) 2009-03-23 2015-11-03 5-β, 14-β-androstane derivatives useful for the treatment of proteinuria, glomerulosclerosis and renal failure

Publications (1)

Publication Number Publication Date
US20120028945A1 true US20120028945A1 (en) 2012-02-02

Family

ID=40622086

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/258,728 Abandoned US20120028945A1 (en) 2009-03-23 2010-03-18 5-Beta, 14-Beta-Androstane Derivatives Useful For The Treatment Of Proteinuria, Glomerulosclerosis And Renal Failure
US14/931,083 Active US9868757B2 (en) 2009-03-23 2015-11-03 5-β, 14-β-androstane derivatives useful for the treatment of proteinuria, glomerulosclerosis and renal failure

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/931,083 Active US9868757B2 (en) 2009-03-23 2015-11-03 5-β, 14-β-androstane derivatives useful for the treatment of proteinuria, glomerulosclerosis and renal failure

Country Status (21)

Country Link
US (2) US20120028945A1 (es)
EP (1) EP2411015B1 (es)
JP (1) JP5738267B2 (es)
KR (1) KR101656797B1 (es)
CN (1) CN102361643B (es)
AU (1) AU2010227644B2 (es)
BR (1) BRPI1012240A2 (es)
CA (1) CA2754642C (es)
DK (1) DK2411015T3 (es)
EA (1) EA019929B1 (es)
ES (1) ES2559005T3 (es)
HU (1) HUE027408T2 (es)
IL (1) IL214477A (es)
MX (1) MX2011009321A (es)
NZ (1) NZ594412A (es)
PL (1) PL2411015T3 (es)
PT (1) PT2411015E (es)
SG (2) SG2014010912A (es)
UA (1) UA103664C2 (es)
WO (1) WO2010108855A1 (es)
ZA (1) ZA201107647B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11337988B2 (en) 2018-09-27 2022-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of ouabain antagonists to inhibit viral infection

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02347B (me) * 2009-10-19 2016-06-20 Rostaquo S P A Rostafuroksin za farmakogenomsko lečenje kardiovaskularnih stanja
CN102940640A (zh) * 2012-12-06 2013-02-27 中国生命药物治疗有限公司 罗他夫辛在制备治疗基因缺陷型原发性高血压的药物中的用途
CN105078954A (zh) * 2015-08-20 2015-11-25 南京华宽信息咨询中心 一种治疗急性肾衰药物及其应用
CN108152432B (zh) * 2017-12-29 2020-11-20 兆科药业（合肥）有限公司 一种罗他夫辛片高效液相检测方法
ES2970792T3 (es) * 2019-10-09 2024-05-30 Windtree Therapeutics Inc Derivados de androstano con actividad como estimuladores puros o predominantemente puros de SERCA2A para el tratamiento de la insuficiencia cardíaca

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227616C2 (de) * 1992-08-20 1995-04-13 Sigma Tau Ind Farmaceuti 17-(3-Furyl)-und 17-(4-Pyridazinyl)-5beta, 14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammemsetzungen
DE4232681C2 (de) 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
DE4232638C2 (de) 1992-09-29 1994-11-17 Sigma Tau Ind Farmaceuti 17-Phenyl-5beta-14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
TWI389917B (zh) * 2006-04-13 2013-03-21 Sigma Tau Ind Farmaceuti 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物
TWI392682B (zh) * 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物
TWI372762B (en) * 2006-06-23 2012-09-21 Sigma Tau Ind Farmaceuti Amino derivatives of b-homoandrostanes and b-heteroandrostanes
HUE025599T2 (en) * 2007-06-07 2016-05-30 Sigma Tau Ind Farmaceuti 5ß, 14β-androstane derivatives for treating diseases caused by organ fibrosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Gooz, "Role of Metalloenzymes, Pathomechanism of Tissue Fibrosis", Science Daily, 2007. *
Kuusniemi et al., "Kidneys with heavy proteinuria show fibrosis, inflammation, and oxidative stress, but no tubular phenotypic change" Kidney International, Vol. 68, pages 121-132, 2005. *
Naderi et al., "Primary Care Approach to Proteinuria." J. Am. Board Fam. Med. 21, 569-574, 2008. *
Ravera et al., "Importance of Blood Pressure Control in Chronic Kidney Disease." J. Am. Soc. Nephrol. 17, S98-S103, 2006. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11337988B2 (en) 2018-09-27 2022-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of ouabain antagonists to inhibit viral infection

Also Published As

Publication number Publication date
CA2754642C (en) 2016-11-08
EA201171155A1 (ru) 2012-03-30
PL2411015T3 (pl) 2016-05-31
IL214477A (en) 2017-04-30
ES2559005T3 (es) 2016-02-10
WO2010108855A1 (en) 2010-09-30
NZ594412A (en) 2013-10-25
EA019929B1 (ru) 2014-07-30
US20160251392A1 (en) 2016-09-01
MX2011009321A (es) 2011-10-03
CN102361643A (zh) 2012-02-22
JP5738267B2 (ja) 2015-06-24
JP2012521383A (ja) 2012-09-13
AU2010227644A1 (en) 2011-09-01
BRPI1012240A2 (pt) 2018-06-12
CA2754642A1 (en) 2010-09-30
SG2014010912A (en) 2014-06-27
SG174260A1 (en) 2011-10-28
IL214477A0 (en) 2011-09-27
UA103664C2 (ru) 2013-11-11
EP2411015B1 (en) 2015-12-23
CN102361643B (zh) 2016-05-18
HUE027408T2 (en) 2016-10-28
PT2411015E (pt) 2016-02-26
KR101656797B1 (ko) 2016-09-12
ZA201107647B (en) 2012-07-25
DK2411015T3 (en) 2016-02-08
EP2411015A1 (en) 2012-02-01
AU2010227644B2 (en) 2016-05-19
US9868757B2 (en) 2018-01-16
KR20110133027A (ko) 2011-12-09

Similar Documents

Publication Publication Date Title
US9868757B2 (en) 5-β, 14-β-androstane derivatives useful for the treatment of proteinuria, glomerulosclerosis and renal failure
US20100093687A1 (en) Method Of Treating Disorder Related To High Cholesterol Concentration
US20040019027A1 (en) Method of treating cerebrotendinous xanthomatosis
JP2001510200A (ja) ステロイドスルファターゼ阻害剤並びにその製造及び使用方法
JPWO2005097097A1 (ja) Ｆｘｒ活性化を介したコレステロールホメオスタシス関連遺伝子転写活性調節剤
JPH07149790A (ja) 新規な１１−ベンズアルドキシム−１７β−メトキシ−１７α−メトキシメチル−エストラジエン誘導体、その製法およびその物質を含有する医薬製剤
EP3730509A1 (en) Compound for treating metabolic diseases and preparation method and use thereof
Na et al. Protective effects of astragaloside in rats with adriamycin nephropathy and underlying mechanism
WO2023273364A1 (zh) 聚乙二醇脂质及其应用
Zhang et al. The ileum-liver Farnesoid X Receptor signaling axis mediates the compensatory mechanism of 17α-ethynylestradiol-induced cholestasis via increasing hepatic biosynthesis of chenodeoxycholic acids in rats
WO2005092328A1 (ja) Ｆｘｒ活性化化合物
EP0414606B1 (fr) Nouveaux acides oméga-phénylamino alcanoiques substitués sur le noyau aromatique par un radical dérivé de 19-nor stéroides, leurs sels, leur procédé de préparation et les intermédiaires de ce procédé, leur application à titre de médicaments et les compositions les renfermant
ZA200210214B (en) Neuroprotective 7-beta-hydroxysteroids.
US20030166626A1 (en) 7-Hydroxyepiandrosterone having neuroprotective activity
Chiang Linking long noncoding RNA to control bile acid signaling and cholestatic liver fibrosis
EP2160190B1 (en) 5beta, 14beta-androstane derivatives useful for the treatment of diseases due to organ fibrosis
WO1998028324A9 (fr) Steroides substitues en position 11, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
WO2001044267A1 (de) 11-β-PHENYLESTRADIEN-DERIVATE MIT FLUORALKYLGRUPPEN IN DER AROMATISCHEN SEITENKETTE, DEREN HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
US20100168129A1 (en) Drugs with anticholestatic activity
WO1994004556A1 (en) Aminofurostenes, compositions, and methods of use
Axelsson et al. Soft Steroids
Brattsand Soft Steroids
Zhou et al. Gastrodia Uncaria Granules: Modulating Hypertension via the FXR-FGF15-CYP7A1 Pathway in Ascendant Hyperactivity of Liver Yang

Legal Events

Date Code Title Description
AS Assignment

Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FERRARI, PATRIZIA;BIANCHI, GIUSEPPE;FERRANDI, MARA;SIGNING DATES FROM 20110905 TO 20110906;REEL/FRAME:026949/0380

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION